Literature DB >> 1104966

An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis.

G B Ryan, M J Karnovsky.   

Abstract

Sprague-Dawley rats injected i.v. with a single dose of puromycin aminonucleoside (PAN) developed massive proteinuria five days later. Electron microscopic studies of perfusion-fixed glomeruli showed that loss of epithelial foot processes and their replacement by flattened expanses of epithelial cytoplasm began at two days and was extensive by four days after the injection of PAN. At and after five days (correlating with the onset and persistence of massive proteinuria), areas of focal loss of the epithelial covering on the outside of the glomerular basement membrane (GBM) were observed in 30% of glomeruli. Intravenously administered ferritin was distributed normally in most sections of the GBM of nephrotic animals, but abnormally deep penetration of particles was observed in GBM segments that lacked an external covering of epithelium. The same changes were found following in situ fixation of superficially placed glomeruli of Munich-Wistar rats with PAN nephrosis. We propose that the massive, early proteinuria in PAN nephrosis may be primarily due to a glomerular epithelial lesion, leading to scattered focal defects in the external covering of the GBM. Increased bulk flow of glomerular filtrate across the GBM in such areas may explain the highly selective proteinuria found in this form of the nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1104966     DOI: 10.1038/ki.1975.105

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  71 in total

1.  Morphological Processes of Foot Process Effacement in Puromycin Aminonucleoside Nephrosis Revealed by FIB/SEM Tomography.

Authors:  Koichiro Ichimura; Takayuki Miyaki; Yuto Kawasaki; Mui Kinoshita; Soichiro Kakuta; Tatsuo Sakai
Journal:  J Am Soc Nephrol       Date:  2018-12-04       Impact factor: 10.121

2.  Investigations on the cause of the nephrotic syndrome in renal amyloidosis. A discussion of electron microscopic findings.

Authors:  H Gise; E Mikeler; M Gruber; H Christ; A Bohle
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1978-08-22

3.  Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury.

Authors:  Jun Zou; Eishin Yaoita; Yusuke Watanabe; Yutaka Yoshida; Masaaki Nameta; Huiping Li; Zhenyun Qu; Tadashi Yamamoto
Journal:  Virchows Arch       Date:  2006-01-18       Impact factor: 4.064

4.  Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition.

Authors:  J R Diamond; S Anderson
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

Review 5.  Proteinuria in a child with sialidosis: case report and histological studies.

Authors:  C E Kashtan; T E Nevins; Z Posalaky; R L Vernier; A J Fish
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

6.  Lymphocyte blastogenesis in nephrotic syndrome.

Authors:  M A Minchin; K J Turner; G D Bower
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

7.  Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis.

Authors:  C I Whiteside; R Cameron; S Munk; J Levy
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  Effects of the aminonucleoside of puromycin on glomerular epithelial cells in vitro.

Authors:  J A Fishman; M J Karnovsky
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

9.  Cytoskeletal changes in podocytes associated with foot process effacement in Masugi nephritis.

Authors:  I Shirato; T Sakai; K Kimura; Y Tomino; W Kriz
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  Glomerular basement membrane anionic charge site changes early in aminonucleoside nephrosis.

Authors:  J D Mahan; S Sisson-Ross; R L Vernier
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.